<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063892</url>
  </required_header>
  <id_info>
    <org_study_id>GG082015</org_study_id>
    <nct_id>NCT03063892</nct_id>
  </id_info>
  <brief_title>Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion</brief_title>
  <official_title>Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregory Georgiadis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProMedica Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty
      to reduce the need for intraoperative and postoperative blood transfusions. Limited research
      is available on its use in hip fracture patients. We hypothesize that the use of TXA
      preoperatively, perioperatively, and postoperatively will decrease blood loss and need for
      blood transfusion postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients requiring packed Red Blood Cell transfusion</measure>
    <time_frame>72 hours</time_frame>
    <description>units, perioperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>24 hours</time_frame>
    <description>mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative anemia</measure>
    <time_frame>72 hours</time_frame>
    <description>Hgb &lt;7g/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (TXA)</intervention_name>
    <description>Tranexamic acid is an antifibrinolytic used to control bleeding</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Saline solution is used as the placebo comparator</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over the age of 60 years

          -  Hip fracture requiring surgical intervention

          -  Signs consent and agrees to participate

        Exclusion Criteria:

          -  Under the age of 60

          -  Does not sign consent or refuses participation

          -  Known hypersensitivity to tranexamic acid

          -  Multiple acute fractures

          -  Creatinine clearance &lt;30

          -  History of seizures

          -  Active hormone therapy

          -  History of coagulation abnormality

          -  History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year
             or history or recurrent DVT/PE

          -  Myocardial infarction (MI) and/or stents within the past year

          -  History of intracranial hemorrhage

          -  Acquired defective color vision

          -  Patients admitted directly to nursing units or surgery without stay in the Emergency
             Center

          -  Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Georgiadis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProMedica Toledo Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Friar</last_name>
    <phone>419-291-1226</phone>
    <email>heather.friar@promedica.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beth Martin, RPh</last_name>
    <phone>419-291-3875</phone>
    <email>beth.martin@promedica.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Georgiadis, MD</last_name>
      <phone>419-291-3858</phone>
      <email>gregory.georgiadisMD@promedica.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>ProMedica Health System</investigator_affiliation>
    <investigator_full_name>Gregory Georgiadis</investigator_full_name>
    <investigator_title>Orthopedic Department Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

